Matt Reed (Nob Hill Therapeutics)
Overview
Matt Reed is a renowned inhalation toxicologist and the Chief Scientific Officer (CSO) of Nob Hill Therapeutics (NHT), a company focused on creating innovative inhalation therapies to treat respiratory conditions. The company is known for its DryNeb technology, a pioneering dry powder nebulizer aiming to deliver medications directly to the lungs. Dr. Reed has over three decades of experience in inhalation toxicology and plays a pivotal role in advancing NHT’s scientific and clinical efforts.
Recent Developments
In recent years, Matt Reed and Nob Hill Therapeutics have made significant strides in the field of inhalation therapy, particularly concerning their DryNeb technology and various therapeutic applications.
- 2024: NHT secured $3 million in Series A funding led by Tramway Venture Partners. This funding is vital for advancing their high-dose respiratory technologies and conducting pre-investigational new drug studies. This financial boost also led to key strategic appointments on the Board of NHT.
- 2023: NHT continued its research on the development of NH101, a dry powder formulation of Amphotericin B designed to treat susceptible and multidrug-resistant Aspergillus infections, under a Phase II SBIR grant. The project focused on refining the DryNeb technology for clinical readiness, emphasizing its potential in targeting multidrug-resistant fungal strains associated with severe respiratory conditions.
- 2022: NHT made substantial progress by achieving key milestones in the preclinical development of inhalation therapies using the DryNeb platform. The company aimed to expand the application of DryNeb-based therapies beyond fungal infections to conditions like cystic fibrosis and lung cancer.
- 2022: The company was invited to present at major conferences such as the Respiratory Drug Delivery meeting (RDD) and an inhalation drug delivery conference, aiming to increase visibility and garner more support from investors and partners.
Personal Information
| Attribute | Information |
|---|---|
| Full Name | Matthew Reed |
| Born | Date and place not publicly available |
| Nationality | American |
| Occupation | Inhalation Toxicologist, Chief Scientific Officer |
| Known For | Dry powder nebulizer technology, NHT innovations |
| Net Worth | Not publicly available |
| Education | PhD in a relevant scientific field (specifics not available) |
Early Life and Education
Specific details about Matt Reed’s early life and education are sparse. It is known that he pursued advanced studies in the fields related to toxicology and respiratory medicine, which laid the foundation for his expertise in inhalation toxicology. Before his current role at Nob Hill Therapeutics, Matt Reed had a significant career at Lovelace Respiratory Research Institute, marking his position in the field with considerable achievements and contributions to science.
Career and Notable Achievements
Matt Reed’s professional journey is marked by pivotal roles in both academia and industry, contributing significantly to inhalation toxicology and respiratory drug delivery.
- Lovelace Respiratory Research Institute: During his tenure, Dr. Reed established himself as a leader in inhalation toxicology, focusing on hazard assessment and the development of drugs delivered via inhalation.
- Nob Hill Therapeutics (NHT): At NHT, as the Chief Scientific Officer, he has been instrumental in the development of the DryNeb platform, a technology that merges the benefits of dry powder inhalers and nebulizers.
- Innovations in Inhalation Therapy: Dr. Reed’s work aims to improve drug delivery methods, specifically targeting the efficacious treatment of respiratory infections, particularly those involving multidrug-resistant pathogens.
Current Work and Impact
Currently, Matt Reed is deeply involved with the advancement of DryNeb technology at Nob Hill Therapeutics. His work continues to impact the development of inhalation therapies, focusing on reducing the complexity and inefficacies of traditional inhalation drugs, thereby expanding the technological horizons of respiratory medicine. Nob Hill Therapeutics, under his guidance, is working on therapies that hold the potential to shift current paradigms in respiratory treatment.
Conclusion
Matt Reed’s career exemplifies a dedicated pursuit of innovation in the realm of inhalation therapy and respiratory toxicology. His contributions to Nob Hill Therapeutics and the development of the DryNeb platform signify a promising advancement in treating complex pulmonary conditions. Looking forward, his work is expected to continue influencing the field, offering impactful solutions for patients with challenging and underserved respiratory needs.